| Hypothyroidism and thyroiditis after therapy for Hodgkin’s disease Á Illés, E Bíró, Z Miltényi, K Keresztes, L Váróczy, C András, S Sipka, ... Acta haematologica 109 (1), 11-17, 2002 | 63 | 2002 |
| Successful immunomodulatory therapy in castleman disease with paraneoplastic pemphigus vulgaris Z Miltenyi, J Toth, A Gonda, I Tar, E Remenyik, A Illes Pathology & Oncology Research 15, 375-381, 2009 | 44 | 2009 |
| Radiation-induced coronary artery disease in Hodgkin's disease Z Miltényi, K Keresztes, I Garai, I Édes, Z Galajda, L Tóth, Á Illés Cardiovascular Radiation Medicine 5 (1), 38-43, 2004 | 36 | 2004 |
| Epidural malignant lymphomas of the spine: collected experiences with epidural malignant lymphomas of the spinal canal and their treatment G Székely, Z Miltényi, G Mezey, Z Simon, J Gyarmati, L Gergely, L Bognár, ... Spinal Cord 46 (4), 278-281, 2008 | 31 | 2008 |
| Employment status and health related quality of life among Hodgkin-lymphoma survivors’–results based on data from a major treatment center in Hungary F Magyari, K Kósa, R Berecz, A Illés, Z Miltényi, Z Simon, Á Illés Health and quality of life outcomes 15, 1-9, 2017 | 29 | 2017 |
| Effect of bleomycin hydrolase gene polymorphism on late pulmonary complications of treatment for Hodgkin lymphoma Á Jóna, Z Miltényi, S Póliska, BL Bálint, Á Illés PLoS One 11 (6), e0157651, 2016 | 27 | 2016 |
| Effect of bleomycin hydrolase gene polymorphism on late pulmonary complications of treatment for Hodgkin lymphoma Á Jóna, Z Miltényi, S Póliska, BL Bálint, Á Illés PLoS One 11 (6), e0157651, 2016 | 27 | 2016 |
| Mediastinal bulky tumour in Hodgkin’s disease and prognostic value of positron emission tomography in the evaluation of post-treatment residual masses K Keresztes, Z Lengyel, K Devenyi, G Vadasz, Z Miltenyi, A Illes Acta haematologica 112 (4), 194-199, 2004 | 27 | 2004 |
| Association between the Epstein-Barr virus and Hodgkin’s lymphoma in the North-Eastern part of Hungary: effects on therapy and survival K Keresztes, Z Miltenyi, B Bessenyei, Z Beck, Z Szollosi, Z Nemes, E Olah, ... Acta haematologica 116 (2), 101-107, 2006 | 23 | 2006 |
| HCV and HGV infection in Hodgkin’s disease K Keresztes, M Takács, M Horányi, Z Miltényi, Á Illés Pathology & Oncology Research 9, 222-225, 2003 | 23 | 2003 |
| Brentuximab vedotin for treating Hodgkin’s lymphoma: an analysis of pharmacology and clinical efficacy Á Illés, Á Jóna, Z Miltényi Expert opinion on drug metabolism & toxicology 11 (3), 451-459, 2015 | 22 | 2015 |
| Quality of life and fatigue in Hodgkin's lymphoma patients Z Miltényi, F Magyari, Z Simon, Á Illés Tumori Journal 96 (4), 594-600, 2010 | 21 | 2010 |
| Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long term follow-up results Z Molnar, Z Simon, Z Borbenyi, B Deak, L Galuska, K Keresztes, Z Miltenyi, ... Neoplasma 57 (4), 349-354, 2010 | 21 | 2010 |
| Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity Á Jóna, Z Miltényi, Z Ujj, I Garai, M Szilasi, Á Illés Expert Opinion on Drug Safety 13 (10), 1291-1297, 2014 | 19 | 2014 |
| Malignant lymphomas and autoimmunity—a single center experience from Hungary L Váróczy, E Páyer, Z Kádár, L Gergely, Z Miltényi, F Magyari, P Szodoray, ... Clinical rheumatology 31, 219-224, 2012 | 19 | 2012 |
| Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma Z Simon, S Barna, Z Miltenyi, K Husi, F Magyari, A Jona, I Garai, Z Nagy, ... International journal of hematology 103, 63-69, 2016 | 18 | 2016 |
| Rare association of Hodgkin lymphoma, Graves’ disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility? Z Simon, Z Ress, J Toldi, A Trauninger, Z Miltényi, Á Illés International journal of hematology 89, 523-528, 2009 | 17 | 2009 |
| Hypokalemic myopathy in a patient with gluten-sensitive enteropathy and dermatitis herpetiformis Duhring: a case report Z Barta, Z Miltenyi, L Toth, A Illes World Journal of Gastroenterology: WJG 11 (13), 2039, 2005 | 15 | 2005 |
| Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients? L Váróczy, L Gergely, Z Miltényi, M Aleksza, Á Illés Immunology letters 97 (1), 155-157, 2005 | 13 | 2005 |
| Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical … LI Pinczés, R Szabó, Á Illés, D Földeák, K Piukovics, Á Szomor, L Gopcsa, ... Annals of Hematology 99, 2385-2392, 2020 | 12 | 2020 |
a illesUniversity of DebrecenE-mail megerősítve itt: med.unideb.hu
